Related Experiment Videos
Biological agents in psoriatic arthritis
Roland Kocijan1, Christian Muschitz, Jürgen Rech
1Medical Department II, St. Vincent Hospital,Academic Teaching Hospital of Medical University of Vienna, The VINFORCE Study Group, Stumpergasse 13, 1060, Vienna, Austria, roland.kocijan@bhs.at.
Wiener Medizinische Wochenschrift (1946)
|September 11, 2014
Summary
Anti-tumor necrosis factor (TNF) therapies effectively treat psoriatic arthritis symptoms and slow disease progression. Combination therapy with other drugs plays a minor role, and anti-TNFs are generally well-tolerated.
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Background:
- Psoriatic arthritis (PsA) is a chronic inflammatory condition affecting joints and skin.
- Tumor necrosis factor (TNF) inhibitors are established treatments for PsA.
Purpose of the Study:
- To review the efficacy and safety of anti-TNF therapies in psoriatic arthritis.
- To discuss the role of combination therapy and emerging biological agents.
Main Methods:
- Literature review of clinical trials and observational studies on anti-TNF agents in PsA.
- Analysis of data on symptom reduction, radiographic progression, and adverse events.
- Consideration of alternative biologic therapies like ustekinumab.
Main Results:
- Anti-TNF therapy significantly reduces pain, inflammation, enthesitis, dactylitis, and skin/nail psoriasis in PsA patients.
- Radiographic progression of PsA is decelerated by anti-TNF treatment.
- Adverse events associated with anti-TNF therapy are comparable to those in rheumatoid arthritis patients.
- The efficacy of anti-TNF agents appears independent of concomitant synthetic disease-modifying anti-rheumatic drugs (DMARDs).
Conclusions:
- Anti-TNF therapies are highly effective and generally well-tolerated for managing psoriatic arthritis.
- Combination therapy with conventional DMARDs has a limited additional benefit in PsA.
- Ustekinumab, targeting IL-12/IL-23, represents a promising alternative biologic treatment for PsA.
Related Concept Videos
01:24T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
478
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
478
01:11Genome-wide Association Studies-GWAS
15.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.3K
01:20The JAK-STAT Signaling Pathway
11.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.9K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480